Indoco Remedies Ltd

Indoco Remedies Other Announcement

Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.

Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr

Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.

Value

₹0.01 Cr

Indoco Remedies Annual General Meeting

Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.

Indoco Remedies Promoter Buying

Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.

Promoter stake change

+0.04%

Indoco Remedies Promoter Buying: ₹0.92 Cr

Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.

Value

₹0.92 Cr

Indoco Remedies Business Update

Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.

Indoco Remedies Promoter Buying: ₹0.1 Cr

Promoters Aditi M. Panandikar and Madhura Suresh Kare each purchased 2,000 shares of Indoco Remedies from the open market. This reflects an increased promoter stake.

Value

₹0.10 Cr

Indoco Remedies Promoter Buying

Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired 10,000 equity shares of Indoco Remedies Limited. This open-market purchase increases the promoter group stake from 5.85% to 5.86%.

Indoco Remedies Promoter Buying: ₹0.24 Cr

Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a total of 10,000 equity shares of Indoco Remedies Ltd through market purchases.

Value

₹0.24 Cr

Indoco Remedies Business Update

Indoco Remedies Limited has executed a Deed of Conveyance to sell a plot of land located at Mahal Industrial Estate to Kalpataru Townships Private Limited.

Indoco Remedies Business Update

Indoco Remedies has executed a deed of conveyance to sell a land plot in Mumbai for a total consideration of ₹64 Crore.

Value

₹64.00 Cr

Indoco Remedies Other Announcement

Indoco Remedies has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-2026. The report provides disclosures on ESG, operations, and governance.

Indoco Remedies Annual Report

Indoco Remedies Limited has scheduled its 79th Annual General Meeting for September 17, 2026. The company also released its comprehensive Annual Report for the 2025-26 financial year.

Indoco Remedies Annual General Meeting

Indoco Remedies Limited fixed September 10, 2026, as the record date for a final dividend of Rs. 0.20 per share. The 79th AGM is scheduled for September 17, 2026.

Indoco Remedies Investor Presentation: Key Takeaways

Indoco Remedies reported Q1FY27 consolidated revenue of INR 4,662 million, up 8.2% YoY. Management focuses on debt reduction, operational efficiency, and scaling domestic mid-sized brands while awaiting USFDA audits.

Call

Guides 11% growth

Indoco Remedies Management Change

Indoco Remedies Limited re-appointed Ms. Aditi Panandikar as Managing Director for a five-year term. Mr. Sudhir Kadam was also appointed as Senior Management Personnel.

Execution

5 years

Indoco Remedies Q1 FY27 Results: Turns Profitable, Net Profit ₹65.4 Cr

Indoco Remedies Ltd reported revenue from operations of ₹466.2 Cr (+8.2% YoY) and net profit of ₹65.4 Cr for Q1 FY27.

Key figure

Net profit ₹65.4 Cr

Indoco Remedies Board Meeting Date

Indoco Remedies will hold a board meeting on July 28, 2026. The board will consider unaudited standalone and consolidated financial results for June quarter.